Drugs that mediate ICB by targeting the inhibitory receptors CTLA-4 and PD-1 (Figure 2inset panel) have been shown to induce durable responses in subsets of patients with various types of cancer including melanoma, NSCLC, and renal cell cancer (RCC) (187–190). This evidence concerns the gene CTLA4 and renal cell adenocarcinoma.